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Abstract
As an Immune checkpoint blockade therapy (ICB), nivolumab has demonstrated efficacy in
Acute Myeloid Leukemia (AML) and various other malignancies. Nivolumab is used as an
anti-programmed cell death 1 (PD-1) agent. The toxicities are observed in more than 10%
of patients, because of its ability,  anti-PD-1 will  upregulate the activity of T-cells.  Over-
activated T-cells will cause immune-related adverse events such as Aplastic Anemia (AA).
Here, we present a case of an over 60-years old male patient with AML, and the possibility
for him to receive an allogeneic hematopoietic stem cell transplantation (allo-HSCT). The
patient  was  treated  with  nivolumab and  subsequently  developed  AA.  As  an  additional
consideration,  we  will  also  discuss  whether  allo-HSCT  is  transplantable  when  AA  is
performed during the treatment of AML.
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Introduction
AML is a type of blood cancer with excess immature white blood cells in bone marrow.
AML- associated regulatory  T-cells  (Tregs)  will  downregulate  the function of  adoptively
transferred cytotoxic T-cells in vivo, and Tregs depletion followed by PD-1 inhibitor such as
nivolumab will result in a superior anti-AML ability (Sehgal et al. 2015) This mechanism of
nivolumab in AML is also likely to over-activate the T-cells which causes immune-related
adverse events such as AA (Comito et al. 2017). Nivolumab is approved in the US for pre-
and post- allo-HSCT treatment to prevent relapse and graft versus host disease (GVHD)
(Herbaux et  al.  2017).  Immune-related  adverse event  AA presenting  before  allo-HSCT
during the nivolumab treatment  for  AML could be an indication of  relapse after  HSCT.
However,  very  limited  research  has  been  done  to  investigate  how  AA  secondary  to
nivolumab therapy may affect the outcome of HSCT.
Case report 
A 61-year-old Caucasian male was diagnosed with AML and detected mutations of DNA
(cytosine-5)-methyltransferase  3  alpha  (DNMT3A)  by  next-generation  sequencing.  The
bone marrow biopsy was performed 3 months before presentation and found no evidence
of  AA;  the  patient  had  no  personal  or  family  history  of  AA.  Laboratory  investigations
revealed white blood cell count (WBC) 44×109/L with 86% blasts, hemoglobin 8.1 g/dL and
a platelet count of 37×109/L. After obtaining an informed consent, the patient was treated
with an induction chemotherapy with IA regimen (cytarabine 1.5 g/m2 by vein daily on days
1-3, with idarubicin 12 mg/m2 by vein daily on days 1-3). After the first week of treatment,
the patient’s WBC count fell to 36×109/L with a significant decrease in blast cell count. The
patient  had  diarrhea,  dizziness  and  headache  which  was  most  likely  caused  by
chemotherapy, according to the comprehensive review of systems. It reveals the patient
reported no other adverse reaction besides common side effects of IA regimen from the
chemotherapy.On day 8, the first dose of nivolumab (1 mg/kg by vein) was started without
induction  chemotherapy  and  continued  every  two  weeks  for  10  cycles.  No  adverse
reactions developed nor was there any disease progression. On day 138, the 11th dose of
nivolumab  was  administered,  and  patient’s  platelet  count  was  53×109/L.  However,
immediately after the 11th dose, there was a sudden decrease in platelet count to 32×109/
L.  As  the  following  12th  dose  of  nivolumab  was  served,  the  patient’s  platelet  counts
gradually dropped to 5×109/L. This result may reveal bone marrow damage, and it was
possibly  attributed  to  the  nivolumab  treatment. The  patient’s  bone  marrow  biopsy  and
aspirate was conducted. The images illustrated lacking of trilineage marrow elements, and
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a hypocellular marrow with global trilineage hypoplasia, (Figs 1, 2) which are consistent
with AA. From day 170 to day 179,  the patient  was administered with a high dose of
methylprednisolone (2 mg/kg/day) intravenously, and from day 180 to 190, the dosage was
reduced to  1  mg/kg/day.  Patient  responded well  to  the  steroid  therapy with  recovered
platelet  and hemoglobin  count.  Due to  the  development  of  presumed grade 2/4  drug-
mediated autoimmune complication, the patient responded well to the steroid therapy. In
this case, stop administrate nivolumab during the AML treatment, will put patient at high
risk for relapse. After all the consideration, the patient was restarted on nivolumab on day
216  and  229,  the  13th  and  14th  dose  of  nivolumab  was  administered,  WBC  count
increased to 52×109/L with less than 10% blast cell counts (Fig. 3). Although the minimal
residual disease (MRD) monitoring has significance impact on prognostic, it remains to be
determined  which  molecular  markers  are  the  most  suitable  for  MRD  monitoring,  but
unfortunately, for DNMT3A mutations were not correlated to relapse after long follow up
clinical  studies,  DNMT3A  is  very  unlikely  suitable  for  any  specific  MRD  detection
(Ossenkoppele and Schuurhuis 2016). Additionally, DNMT3A mutation leads to abnormal
of DNA methylation patterns, which is likely to alter the expression of the various target
genes which indicate their  applicability MRD monitoring remains unclear (Debarri  et  al.
2015). After all the consideration, whether allo-HSCT is transplantable should be discussed
with more discretion. The profile of the patient is provided (Table 1).
The patient characteristics in with AA induced by nivolumab therapy
Gender/age Male/61
Hematology-
Oncology
Acute Myeloid Leukemia with DNMT3A mutation.
Baseline CBC
   Hb (g/dL)
   Plt (×10 /L) 
   WBC (×10 /L) 
 
8.1
37
44
ICB agent/dose Nivolumab (1mg/kg/two weeks)
Presentation of AA 151 days post 12  cycles of Nivolumab.
AA presentation
   Hb (g/dL)
   Plt (×10 /L) 
   WBC (×10 /L) 
 
6.1
5
12
BM biopsy The biopsy of BM reveals the bio-sample lack of hematopoietic elements and hypocellular
marrow.
Treatment of AA Methylprednisolone ×21 days.
AA response Rapid recovery in hemoglobin and neutropenia on day 177.
Patient outcome The patient has reached complete remission, no other adverse reaction is developing and further
HSCT should be considered.
9
9
th
9
9
Table 1. 
The patient characteristics .
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Figure 1. 
Demonstrated a hypocellular marrow with global trilineage hypoplasia.
Figure 2. 
BM  aspirate  demonstrated  a  spicules  composed  of  stromal  components,  but  lacking
trilineage marrow elements.
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Discussion
Addition of nivolumab to IA regimen is safe in older AML patients; although, it may cause
immune-related adverse events  such as AA.  Patients  with  AA receive a destruction of
hematopoietic  cells  by  over-activated  immune  system leads  to  pancytopenia.  Somatic
mutations, DNMT3A-mutated genes, were detected in some of the AML or AA patients
(Kulasekararaj et al. 2014), but clinical work-up and later laboratory investigation illustrated
the patent did not develop AA before the treatment, and it happened after the 11th dose of
nivolumab was received. After AA was developed, it  may have revealed PD-1 inhibitor;
nivolumab is over-activating T-cells, and consequently causes bone marrow damage. Even
though  at  this  case,  immune-mediated  bone  marrow  destruction  is  reversible  by
immunosuppression or withdrawal of the offending agent, but using immunosuppressive
drugs  such  as  methylprednisolone  may  lead  to  delayed  immune  reconstitution  after
a b
c d
Figure 3. 
Efficacy of chemotherapy, nivolumab and methylprednisolone in patient.
After one week DA regimen chemotherapy, patient was stared nivolumab therapy without
continuing chemotherapy. After the 12  dose of nivolumab was administered an AA was
detected. These graph provide last 229 days clinical dates of patient’s platelet, hemoglobin,
WBC and blast cell count.
Organge Box: 1  nivolumab was administered.
Grey diamond: Aplastic anemia was detected.
a: Patient’s platelet count variation graph    
b: Patient’s Hemoglobin variation graph  
c: Patient`s White blood cell count variation graph  
d: Patient`s Blast cell count variation graph  
th
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process allo-HSCT to increase the risk of relapse (Perales and van den Brink 2012). In this
case report, methylprednisolone was administered as an immunosuppression treatment,
and it  could downregulates activates of T-cells.  If  the patient has been processed allo-
HSCT, the recovery of T cell compartment relies on the peripheral expansion of memory T-
cell  (T  lymphocyte),  eventually  leads  to  a  slow  T-cell  reconstitution  and  consequently
causing the relapse (Krenger et al. 2011). However, nivolumab has been approved in the
US to prevent relapse after allo-HSCT. Continuing to administer nivolumab at post stage of
allo-HSCT may specifically help slow T-cell reconstitution-related immune complications or
relapse (Ogonek et al. 2016). Due to the limited amount of research and knowledge on this
clinical case, more studies are needed for further actions on allo-HSCT. 
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